Phase 1 AML Clinical Trials
63 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 63 trials
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 1Phase 2
Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS
Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 1
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
AMLMyelodysplastic SyndromesCML+3 more
University of Alabama at Birmingham50 enrolled1 locationNCT06047886
Recruiting
Phase 1
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)
Acute Myeloid LeukemiaR/R AMLR/R HR-MDS+1 more
Genmab78 enrolled5 locationsNCT07384715
Recruiting
Phase 1
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
AMLMyelodysplastic SyndromesALL, Adult
TScan Therapeutics, Inc.75 enrolled15 locationsNCT05473910
Recruiting
Phase 1
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05756777
Recruiting
Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
B-ALLAML/MDST-ALL+1 more
St. Jude Children's Research Hospital108 enrolled2 locationsNCT04318678
Recruiting
Phase 1
Revumenib in Combination With 7+3 + Midostaurin in AML
Acute Myeloid LeukemiaAMLLeukemia+2 more
Richard Stone, MD22 enrolled2 locationsNCT06313437
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 1
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Acute Myeloid LeukemiaAMLRefractory Acute Myeloid Leukemia
CERo Therapeutics Holdings, Inc.18 enrolled4 locationsNCT06834282
Recruiting
Phase 1Phase 2
Phase IB/II of CPX-351 for Relapse Prevention in AML
Acute Myeloid Leukemia (AML) in Remission
Georgetown University24 enrolled3 locationsNCT04990102
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1Phase 2
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Acute Myeloid Leukemia (AML)CEBPA MutationUnfit, New-diagnosis AML
The First Affiliated Hospital of Soochow University29 enrolled1 locationNCT07451912
Recruiting
Phase 1Phase 2
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
AML, Childhood
Washington University School of Medicine68 enrolled1 locationNCT06158828
Recruiting
Phase 1Phase 2
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
TreatmentAMLIDH1 Mutation
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06611839
Recruiting
Phase 1
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia+9 more
Solu Therapeutics, Inc105 enrolled7 locationsNCT06950034
Recruiting
Phase 1Phase 2
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
LeukemiaBlood CancersBlood Cancer+1 more
Jacqueline Garcia, MD31 enrolled2 locationsNCT07148180
Recruiting
Phase 1
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
LymphomaMDSHematologic Malignancy+2 more
St. Jude Children's Research Hospital18 enrolled1 locationNCT06326463
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1
CC-486 and Venetoclax for Acute Myeloid Leukemia
AML
University of Colorado, Denver35 enrolled2 locationsNCT05287568